EA201791184A1 - Днк-примеси в композиции, содержащей парвовирусный вирион - Google Patents

Днк-примеси в композиции, содержащей парвовирусный вирион

Info

Publication number
EA201791184A1
EA201791184A1 EA201791184A EA201791184A EA201791184A1 EA 201791184 A1 EA201791184 A1 EA 201791184A1 EA 201791184 A EA201791184 A EA 201791184A EA 201791184 A EA201791184 A EA 201791184A EA 201791184 A1 EA201791184 A1 EA 201791184A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virion
parvirus
composition containing
present
composition
Prior art date
Application number
EA201791184A
Other languages
English (en)
Other versions
EA035747B1 (ru
Inventor
Яцек Лубельский
Вильхельмус Теодорус Йоханнес Мария Кристиан Херменс
Original Assignee
ЮНИКЬЮРЕ АйПи Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52000715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791184(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ЮНИКЬЮРЕ АйПи Б.В. filed Critical ЮНИКЬЮРЕ АйПи Б.В.
Publication of EA201791184A1 publication Critical patent/EA201791184A1/ru
Publication of EA035747B1 publication Critical patent/EA035747B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к примесям нуклеиновой кислоты в композиции, содержащей парвовирусный вектор. В частности, настоящее изобретение показывает, что ДНК-примеси инкапсулируются в парвовирусном вирионе не случайным образом. Таким образом, настоящее изобретение относится к способу идентификации и количественного определения примеси нуклеиновой кислоты в композиции, содержащей парвовирусный вектор. Кроме того, настоящее изобретение относится к способу определения того, является ли композиция, содержащая парвовирусный вектор, клинически чистой.
EA201791184A 2014-11-28 2015-11-27 Днк-примеси в композиции, содержащей парвовирусный вирион EA035747B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14195464 2014-11-28
PCT/EP2015/077882 WO2016083560A1 (en) 2014-11-28 2015-11-27 Dna impurities in a composition comprising a parvoviral virion

Publications (2)

Publication Number Publication Date
EA201791184A1 true EA201791184A1 (ru) 2017-09-29
EA035747B1 EA035747B1 (ru) 2020-08-05

Family

ID=52000715

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791184A EA035747B1 (ru) 2014-11-28 2015-11-27 Днк-примеси в композиции, содержащей парвовирусный вирион

Country Status (19)

Country Link
US (2) US11021762B2 (ru)
EP (3) EP3224376B2 (ru)
JP (1) JP6741345B2 (ru)
KR (1) KR102528156B1 (ru)
CN (1) CN107208142B (ru)
AU (1) AU2015352469B2 (ru)
BR (1) BR112017011217A2 (ru)
CA (1) CA2968622A1 (ru)
CY (1) CY1122223T1 (ru)
DK (2) DK3591070T3 (ru)
EA (1) EA035747B1 (ru)
ES (1) ES2751919T5 (ru)
FI (1) FI3224376T4 (ru)
HK (1) HK1244849B (ru)
HU (1) HUE046643T2 (ru)
PL (1) PL3224376T5 (ru)
PT (1) PT3224376T (ru)
SI (1) SI3224376T2 (ru)
WO (1) WO2016083560A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
KR102584655B1 (ko) 2014-11-14 2023-10-06 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CA2968622A1 (en) 2014-11-28 2016-06-02 Uniqure Ip B.V. Dna impurities in a composition comprising a parvoviral virion
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
BR112018073384A2 (pt) 2016-05-18 2019-03-06 Voyager Therapeutics, Inc. polinucleotídeos moduladores
CN110913866A (zh) 2017-05-05 2020-03-24 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
US11980507B2 (en) 2018-05-02 2024-05-14 Augmedics Ltd. Registration of a fiducial marker for an augmented reality system
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
WO2022188797A1 (en) 2021-03-09 2022-09-15 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
CN117660534B (zh) * 2023-12-13 2024-05-07 广州派真生物技术有限公司 一种降低重组腺相关病毒中宿主细胞dna残留的辅助质粒及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0562047A4 (en) * 1990-12-06 1995-11-02 Affymax Tech Nv Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
EP1222299A1 (en) 1999-10-01 2002-07-17 Genovo, Incorporated Production of recombinant aav using adenovirus comprising aav rep/cap genes
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
EP3235827B1 (en) 2003-06-19 2021-01-13 Genzyme Corporation Aav virions with decreased immunoreactivity and uses therefor
CN101018858A (zh) * 2004-06-01 2007-08-15 建新公司 防止aav载体聚集的组合物和方法
SI1945779T1 (sl) 2005-10-20 2013-07-31 Uniqure Ip B.V. Izboljĺ ani aav vektorji proizvedeni v celicah insekta
CA2655957C (en) 2006-06-21 2016-05-03 Amsterdam Molecular Therapeutics (Amt) B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
MX2009002741A (es) * 2006-09-15 2009-05-11 Medimmune Llc Lineas de celulas mdck que soportan el crecimiento viral para altos titulos y proceso de biorreactor que utiliza las mismas.
MX2010000944A (es) 2007-07-26 2010-08-31 Amsterdam Molecular Therapeutics Bv Vectores baculovirales que comprenden secuencias de codificacion repetida con deformaciones diferenciales en codones.
EP2250256B1 (en) 2008-02-19 2017-08-02 uniQure IP B.V. Optimisation of expression of parvoviral rep and cap proteins in insect cells
MX340102B (es) 2010-01-28 2016-06-24 The Children's Hospital Of Philadelphia * Una plataforma de fabricacion ajustable en escala, para la purificacion de vector viral y vectores virales asi purificados para el uso en terapia de genes.
EP3792348A3 (en) * 2010-03-11 2021-06-23 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
KR101334072B1 (ko) * 2010-11-25 2013-11-29 한국표준과학연구원 핵산 정량 방법 및 키트
WO2013011611A1 (ja) 2011-07-19 2013-01-24 株式会社 日立ハイテクノロジーズ 核酸分析方法及び核酸分析装置
FR2986239A1 (fr) 2012-01-31 2013-08-02 Univ Strasbourg Biomarqueur pour les maladies inflammatoires pulmonaires chroniques
JP6093358B2 (ja) * 2012-07-06 2017-03-08 タカラバイオ株式会社 アデノ随伴ウイルスベクターの産生細胞
JP6392222B2 (ja) * 2012-07-24 2018-09-19 ナテラ， インコーポレイテッド 高度多重ｐｃｒ法および組成物
JP2016517278A (ja) 2013-03-15 2016-06-16 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ スタッファー／フィラーポリヌクレオチド配列を含むベクターおよびその使用方法
CA2968622A1 (en) 2014-11-28 2016-06-02 Uniqure Ip B.V. Dna impurities in a composition comprising a parvoviral virion

Also Published As

Publication number Publication date
CN107208142A (zh) 2017-09-26
AU2015352469B2 (en) 2021-09-16
SI3224376T1 (sl) 2020-01-31
HUE046643T2 (hu) 2021-11-29
HK1244849B (zh) 2020-04-09
US11021762B2 (en) 2021-06-01
US20210332447A1 (en) 2021-10-28
JP6741345B2 (ja) 2020-08-19
DK3224376T4 (da) 2023-05-30
SI3224376T2 (sl) 2023-07-31
BR112017011217A2 (pt) 2018-02-06
EA035747B1 (ru) 2020-08-05
JP2017535278A (ja) 2017-11-30
ES2751919T3 (es) 2020-04-02
DK3591070T3 (da) 2023-01-30
EP3591070B1 (en) 2022-12-21
ES2751919T5 (es) 2023-10-04
KR20170081704A (ko) 2017-07-12
PT3224376T (pt) 2019-10-25
AU2015352469A1 (en) 2017-06-01
PL3224376T5 (pl) 2023-08-21
US20170321290A1 (en) 2017-11-09
KR102528156B1 (ko) 2023-05-03
EP4219742A1 (en) 2023-08-02
WO2016083560A1 (en) 2016-06-02
DK3224376T3 (da) 2019-09-30
EP3224376B2 (en) 2023-04-26
EP3591070A1 (en) 2020-01-08
PL3224376T3 (pl) 2020-03-31
CN107208142B (zh) 2024-03-26
CA2968622A1 (en) 2016-06-02
CY1122223T1 (el) 2020-11-25
EP3224376B1 (en) 2019-08-07
EP3224376A1 (en) 2017-10-04
FI3224376T4 (fi) 2023-08-31

Similar Documents

Publication Publication Date Title
EA201791184A1 (ru) Днк-примеси в композиции, содержащей парвовирусный вирион
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
EA201891338A1 (ru) Композиции и способы для иммуноонкологии
EA201891001A1 (ru) Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
MX2022007933A (es) Compuestos de polimetino y su uso como etiquetas fluorescentes.
EA201991105A1 (ru) Методы оценки риска с использованием общей и специфической неклеточной днк
WO2016066756A3 (en) Protease variants and polynucleotides encoding same
WO2016066757A3 (en) Protease variants and polynucleotides encoding same
JP2016525888A5 (ru)
JP2014064590A5 (ru)
EA201792389A1 (ru) Пцр в реальном времени для мультиплексной оптимизированной амплификации с несоответствиями (moma) и для оценки неклеточной днк
EA201792663A1 (ru) Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
WO2016130704A3 (en) Methods and compositions for analyzing cellular components
MX2017007731A (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA201690529A1 (ru) Способы модификации клетки-хозяина
EA202193044A2 (ru) Способы лечения таупатии
EA201692309A1 (ru) Стереохимически обогащенные композиции для доставки нуклеиновых кислот
WO2015024739A3 (en) Detergent composition comprising protease variants
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
GB2537077A (en) Methods for sequencing nucleic acids
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
IN2015DN02793A (ru)
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM